RAD51 inhibitors

A compound represented by the following structural formula:

• or a pharmaceutically acceptable salt thereof, wherein:
• the thiazole ring is optionally substituted with F or Cl;
• Cy is (C3-C7)cycloalkyl, bridged (C6-C12)cycloalkyl, or a 4-10 membered heterocyclic ring, each of which is optionally substituted with one or more groups selected from the group consisting of halogen, OH, (C1-C4)alkyl, and (C1-C4)alkoxy;
• when X5 is connected with a nitrogen ring atom of Cy, X5 is absent;
• when X5 is connected with a carbon ring atom of Cy, X5 is NRa or O;
• X6 is NRa or O;
• R1 is (C1-C5)alkyl optionally substituted with OH;
• R3 is (C1-C5)alkyl, —CH2-phenyl, (C3-C7)cycloalkyl, —CH2—(C3-C7)cycloalkyl, —CH2-monocyclic 3-7 membered heterocyclic ring, or monocyclic 3-7 membered heterocyclic ring, wherein the (C1-C5)alkyl, (C3-C7)cycloalkyl, phenyl, or monocyclic 3-7 membered heterocyclic ring represented by R3 or in the group represented by R3 is optionally substituted with one or more groups selected from the group consisting of halogen, OH, (C1-C4)alkyl, halomethyl, halomethoxy, CN, and (C1-C4)alkoxy;
• R2 is —NRaC(O)O(C1-C4)alkyl, —NRaC(O)NRa(C1-C4)alkyl, —NRaC(O)O(C2-C4)alkenyl, —NRaC(O)NRa(C2-C4)alkenyl, —NRaC(O)O—(C3-C6)cycloalkyl, —NRaC(O)NRa—(C3-C7)cycloalkyl, —NRaC(O)O-phenyl, —NRaC(O)NRa-phenyl, —NRaC(O)O-monocyclic 3-7 membered heterocyclic ring, —NRaC(O)NRa-monocyclic 3-7 membered heterocyclic ring, —NRaC(O)O-monocyclic 5-6 membered heteroaromatic ring, or —NRaC(O)NRa-monocyclic 5-6 membered heteroaromatic ring;
• wherein the (C1-C4)alkyl and the (C2-C4)alkenyl in the group represented by R2 are each optionally and independently substituted with one or more groups selected from the group consisting of halogen, N3, ORa, NRaRa, (C3-C6)cycloalkyl, phenyl, a monocyclic 3-7 membered heterocyclic ring, and a monocyclic 5-6 membered heteroaromatic ring;
• wherein the (C3-C7)cycloalkyl in the group represented by R2 is optionally substituted with one or more groups selected from the group consisting of halogen, CH3, =O, ORa, and NRaRa;
• wherein the phenyl in the group represented by R2 is optionally substituted with one or more groups selected from the group consisting of halogen, CH3, halomethyl, halomethoxy, CN, ORa, and N3;
• wherein the heterocyclic ring in the group represented by R2 is optionally substituted with one or more groups selected from the group consisting of ═O, halogen, ORa, CH3, halomethyl, and halomethoxy;
• wherein the heteroaromatic ring in the group represented by R2 is optionally substituted with one or more groups selected from the group consisting of halogen, CN, CH3, halomethyl, halomethoxy, ORa, and NRaRa;
• and
• each Ra is independently H or CH3.